Literature DB >> 18041083

Lung resection in cystic fibrosis: a survival analysis.

Paulo Camargos1, Muriel Le Bourgeois, Yann Revillon, Edson Tatsuo, Isabelle Sermet-Gaudelus, Pierre Scheinmann, Jacques de Blic.   

Abstract

Lung resection may be considered for cystic fibrosis (CF) patients showing localized severe chronic atelectasis and/or bronchiectasis. Nonetheless, literature on survival after surgery is scarce. This study was carried out to assess survival time after partial lung resection. Twenty-one CF patients were operated from 1988 to 2003 and were followed until November 30th, 2004. Survival analysis was performed through Kaplan-Meier method. Mean age at resection was 8.09 years (SD 4.40 years) and two-thirds were females. Z-scores for height, weight, and body mass index as well as FEV1 values showed no statistical significance when comparing values obtained from 2 years before to 2 years after resection. Eleven years after resection, survival probability was 93.8%. Our results suggest that lobectomy or segmentectomy are safe procedures and should be considered in carefully selected patients with unilateral severe symptomatic localized and chronic persistent atelectasis and/or bronchiectasis refractory to conservative management. Copyright (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2008        PMID: 18041083     DOI: 10.1002/ppul.20742

Source DB:  PubMed          Journal:  Pediatr Pulmonol        ISSN: 1099-0496


  4 in total

1.  Lobectomy in patients with cystic fibrosis.

Authors:  Shahid I Sheikh; Karen S McCoy; Nancy A Ryan-Wenger; Alpa Patel; Stephen Kirkby
Journal:  Can Respir J       Date:  2014-02-12       Impact factor: 2.409

Review 2.  Nontuberculous mycobacteria: the changing epidemiology and treatment challenges in cystic fibrosis.

Authors:  Janice M Leung; Kenneth N Olivier
Journal:  Curr Opin Pulm Med       Date:  2013-11       Impact factor: 3.155

3.  Prevalence and course of disease after lung resection in primary ciliary dyskinesia: a cohort & nested case-control study.

Authors:  Panayiotis Kouis; Myrofora Goutaki; Florian S Halbeisen; Ifigeneia Gioti; Nicos Middleton; Israel Amirav; Angelo Barbato; Laura Behan; Mieke Boon; Nagehan Emiralioglu; Eric G Haarman; Bulent Karadag; Cordula Koerner-Rettberg; Romain Lazor; Michael R Loebinger; Bernard Maitre; Henryk Mazurek; Lucy Morgan; Kim Gjerum Nielsen; Heymut Omran; Ugur Özçelik; Mareike Price; Andrzej Pogorzelski; Deborah Snijders; Guillaume Thouvenin; Claudius Werner; Zorica Zivkovic; Claudia E Kuehni; Panayiotis K Yiallouros
Journal:  Respir Res       Date:  2019-09-18

Review 4.  Infection prevention and chronic disease management in cystic fibrosis and noncystic fibrosis bronchiectasis.

Authors:  Sherstin T Lommatzsch
Journal:  Ther Adv Respir Dis       Date:  2020 Jan-Dec       Impact factor: 4.031

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.